vs

Side-by-side financial comparison of Epsilon Energy Ltd. (EPSN) and Immunovant, Inc. (IMVT). Click either name above to swap in a different company.

Epsilon Energy Ltd. is the larger business by last-quarter revenue ($14.8M vs $8.4M, roughly 1.8× Immunovant, Inc.). Epsilon Energy Ltd. runs the higher net margin — -83.9% vs -899.0%, a 815.1% gap on every dollar of revenue. On growth, Immunovant, Inc. posted the faster year-over-year revenue change (140.7% vs 65.7%).

Epsilon Composite is a French company created in 1987 by Stephane LULL, its current CEO. The company was founded in January 1987. Its production site is located in Gaillan, France. Stéphane Lull is the CEO.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody therapies for patients with serious, rare autoimmune and inflammatory diseases. Its lead product candidate covers multiple autoimmune indications, with core U.S. operations and a global market expansion strategy.

EPSN vs IMVT — Head-to-Head

Bigger by revenue
EPSN
EPSN
1.8× larger
EPSN
$14.8M
$8.4M
IMVT
Growing faster (revenue YoY)
IMVT
IMVT
+75.0% gap
IMVT
140.7%
65.7%
EPSN
Higher net margin
EPSN
EPSN
815.1% more per $
EPSN
-83.9%
-899.0%
IMVT

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
EPSN
EPSN
IMVT
IMVT
Revenue
$14.8M
$8.4M
Net Profit
$-12.4M
$-75.3M
Gross Margin
Operating Margin
-129.0%
-896.2%
Net Margin
-83.9%
-899.0%
Revenue YoY
65.7%
140.7%
Net Profit YoY
-1535.0%
-26.7%
EPS (diluted)
$-0.55
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPSN
EPSN
IMVT
IMVT
Q4 25
$14.8M
Q3 25
$9.0M
Q2 25
$11.6M
Q1 25
$16.2M
Q4 24
$8.9M
Q3 24
$7.3M
Q2 24
$7.3M
Q1 24
$8.0M
$8.4M
Net Profit
EPSN
EPSN
IMVT
IMVT
Q4 25
$-12.4M
Q3 25
$1.1M
Q2 25
$1.6M
Q1 25
$4.0M
Q4 24
$-760.8K
Q3 24
$366.0K
Q2 24
$815.7K
Q1 24
$1.5M
$-75.3M
Operating Margin
EPSN
EPSN
IMVT
IMVT
Q4 25
-129.0%
Q3 25
6.7%
Q2 25
7.1%
Q1 25
44.3%
Q4 24
6.8%
Q3 24
3.3%
Q2 24
16.0%
Q1 24
17.6%
-896.2%
Net Margin
EPSN
EPSN
IMVT
IMVT
Q4 25
-83.9%
Q3 25
11.9%
Q2 25
13.3%
Q1 25
24.8%
Q4 24
-8.5%
Q3 24
5.0%
Q2 24
11.2%
Q1 24
18.9%
-899.0%
EPS (diluted)
EPSN
EPSN
IMVT
IMVT
Q4 25
$-0.55
Q3 25
$0.05
Q2 25
$0.07
Q1 25
$0.18
Q4 24
$-0.04
Q3 24
$0.02
Q2 24
$0.04
Q1 24
$0.07
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPSN
EPSN
IMVT
IMVT
Cash + ST InvestmentsLiquidity on hand
$9.0M
$635.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$124.7M
$617.8M
Total Assets
$228.2M
$666.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPSN
EPSN
IMVT
IMVT
Q4 25
$9.0M
Q3 25
$12.8M
Q2 25
$9.9M
Q1 25
$6.9M
Q4 24
$6.5M
Q3 24
$8.3M
Q2 24
$8.6M
Q1 24
$2.3M
$635.4M
Stockholders' Equity
EPSN
EPSN
IMVT
IMVT
Q4 25
$124.7M
Q3 25
$100.2M
Q2 25
$100.2M
Q1 25
$99.7M
Q4 24
$96.7M
Q3 24
$98.4M
Q2 24
$99.6M
Q1 24
$99.9M
$617.8M
Total Assets
EPSN
EPSN
IMVT
IMVT
Q4 25
$228.2M
Q3 25
$126.3M
Q2 25
$123.6M
Q1 25
$125.5M
Q4 24
$120.5M
Q3 24
$121.8M
Q2 24
$121.1M
Q1 24
$125.1M
$666.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPSN
EPSN
IMVT
IMVT
Operating Cash FlowLast quarter
$-277.0K
$-59.7M
Free Cash FlowOCF − Capex
$-59.8M
FCF MarginFCF / Revenue
-714.4%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-214.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPSN
EPSN
IMVT
IMVT
Q4 25
$-277.0K
Q3 25
$4.0M
Q2 25
$8.3M
Q1 25
$8.6M
Q4 24
$5.0M
Q3 24
$2.7M
Q2 24
$5.4M
Q1 24
$3.7M
$-59.7M
Free Cash Flow
EPSN
EPSN
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-59.8M
FCF Margin
EPSN
EPSN
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-714.4%
Capex Intensity
EPSN
EPSN
IMVT
IMVT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
1.8%
Cash Conversion
EPSN
EPSN
IMVT
IMVT
Q4 25
Q3 25
3.70×
Q2 25
5.38×
Q1 25
2.14×
Q4 24
Q3 24
7.50×
Q2 24
6.60×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPSN
EPSN

Gas Oil Ngls And Condensate$13.3M90%
Gas Gathering And Compression$1.5M10%

IMVT
IMVT

Segment breakdown not available.

Related Comparisons